Order Article Reprints

Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. International Journal of Molecular Sciences. 2019; 20(22):5537. https://doi.org/10.3390/ijms20225537

Yamashita, Shizuya, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideki Suganami, and Shun Ishibashi. 2019. "Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination" International Journal of Molecular Sciences 20, no. 22: 5537. https://doi.org/10.3390/ijms20225537

Yamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2019). Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. International Journal of Molecular Sciences, 20(22), 5537. https://doi.org/10.3390/ijms20225537